Anne Zaki, MD
Ophthalmology · Sun City West, AZNPI 1427014992
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $401,062 of the $518,128 with a category attached, or 77.4%. 30 manufacturers reported payments, led by Tarsus Pharmaceuticals, Inc. at 46.0% of the total. 2025 is the largest year on record at $171,440, 9.3 times the $18,354 reported in 2019. Among ophthalmology clinicians in AZ with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 718 payments — averaging $721.63 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Tarsus Pharmaceuticals, Inc.$238K
- AbbVie$161K
- Dompe US, Inc.$42K
- Sun Pharmaceutical Industries Inc.$27K
- Bausch & Lomb Americas Inc.$19K
- Novartis$12K
- plus $18K from 24 others
What the payments were for
- Consulting fees$47,0089%
- Speaking & faculty fees$401,06277%
- Travel & lodging$49,0199%
- Food & beverage$21,0224%
- Education$180%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Tarsus Pharmaceuticals, Inc. | 179 | $238,275 |
| AbbVie(2 entities) | 237 | $161,042 |
| Dompe US, Inc. | 58 | $42,326 |
| Sun Pharmaceutical Industries Inc. | 67 | $27,394 |
| Bausch & Lomb Americas Inc. | 41 | $18,958 |
| Novartis | 19 | $11,907 |
| Shire North American Group Inc | 13 | $7,035 |
| Rxsight Inc | 6 | $2,967 |
| Kala Pharmaceuticals, Inc. | 13 | $2,850 |
| Alcon | 23 | $2,089 |
| Lumenis BE Inc | 1 | $849 |
| Oyster Point Pharma, Inc. | 12 | $593 |
| Glaukos Corporation | 4 | $357 |
| Aerie Pharmaceuticals, Inc. | 12 | $322 |
| Biotissue Holdings Inc. | 4 | $185 |
| Alimera Sciences, Inc. | 1 | $133 |
| Carl Zeiss Meditec USA, Inc. | 2 | $131 |
| Harrow Eye, LLC | 4 | $92 |
| Sight Sciences, Inc. | 4 | $90 |
| Johnson & Johnson Surgical Vision, Inc. | 3 | $84 |
| Genentech USA, Inc. | 1 | $81 |
| Mallinckrodt Hospital Products Inc. | 3 | $72 |
| Heidelberg Engineering, Inc. | 1 | $68 |
| Amgen | 2 | $53 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 2 | $44 |
| Thea Pharma Inc. | 2 | $37 |
| Ivantis, Inc | 1 | $34 |
| Astellas Pharma US Inc | 1 | $22 |
| ANI Pharmaceuticals, Inc. | 1 | $20 |
| Ocular Therapeutix, Inc. | 1 | $17 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- XDEMVY$219,670
- VUITY$105,971
- Oxervate$41,328
- RESTASIS MULTIDOSE$39,140
- XIIDRA$36,513
- CEQUA$26,397
- MIEBO$17,246
- RXSIGHT CONTACT LENS$2,920
- RXSIGHT INJECTOR CARTRIDGE$2,920
- RXSIGHT INJECTOR HANDPIECE$2,920
- RXSIGHT LIGHT DELIVERY DEVICE (LDD)$2,920
- LIGHT ADJUSTABLE LENS (LAL)$2,785
- EYSUVIS$2,706
- LenSx$1,236
- ALPHAGAN P$984
- LUMIGAN$966
- M22$849
- COMBIGAN$436
- iDoseTR$294
- INVELTYS$246
How this compares
$518,128 in reported general payments places this provider in the 95th percentile of 310 ophthalmology providers in Arizona.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RestasisCyclosporine | 151 | $177,500 |
| XdemvyLotilaner | 90 | $163,424 |
| Cyclosporine | 100 | $79,396 |
| CequaCyclosporine | 37 | $42,609 |
| LumiganBimatoprost | 28 | $19,289 |
| Prednisolone Acetate | 377 | $18,016 |
| Lotemax SmLoteprednol Etabonate | 69 | $17,884 |
| MieboPerfluorohexyloctane/Pf | 18 | $13,372 |
| Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol | 40 | $8,162 |
| RocklatanNetarsudil Mesylat/Latanoprost | 22 | $7,966 |
| MoxifloxacinMoxifloxacin Hcl | 394 | $7,731 |
| Loteprednol Etabonate | 25 | $6,162 |
| Latanoprost | 288 | $4,802 |
| Brimonidine Tartrate | 35 | $3,273 |
| Travoprost | 17 | $2,752 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieRestasis, Lumigan | $161,042 | $196,790179 claims |
| Tarsus Pharmaceuticals, Inc.Xdemvy | $238,275 | $163,42490 claims |
| Sun Pharmaceutical Industries Inc.Cequa | $27,394 | $42,60937 claims |
| Bausch & Lomb, A Division Of Bausch Health US, LLCLotemax Sm, Loteprednol Etabonate | $44 | $24,04694 claims |
| Bausch & Lomb Americas Inc.Miebo | $18,958 | $13,37218 claims |
| Aerie Pharmaceuticals, Inc.Rocklatan | $322 | $7,96622 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 310 ophthalmology providers in Arizona.
Other ophthalmology in Sun City West
- Warren HillMesa$1.1M
- Mark BarakatScottsdale$794K
- Pravin DugelPhoenix$176K
- Derek KunimotoMesa$138K
- Shamil PatelGlendale$116K
- Yuri McKeeMesa$100K
- Nishi ShahPhoenix$92K
- Lisa MihoraPeoria$91K
- George ReissGlendale$73K
- Wendy HuangGlendale$73K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.